Akela Pharma Inc

Akela Pharma Inc. is a privately held, integrated product development company based in Austin, Texas. The company employs 17 individuals and generates an annual revenue of $2.5 million. Akela Pharma specializes in developing therapeutics for pain management, leveraging its proprietary drug delivery technologies. Their lead product candidate, Fentanyl TAIFUN®, is a fentanyl formulation designed for delivery via their TAIFUN® Multi-Dose Inhaler. This inhaled opioid analgesic is being developed to rapidly address breakthrough cancer pain, offering potentially faster pain relief at lower dosages compared to existing non-injectable options. In June 2007, Akela Pharma entered into an exclusive license and development agreement with Janssen Pharmaceutica N.V. to further develop and commercialize Fentanyl TAIFUN®. Akela Pharma believes that, if approved, Fentanyl TAIFUN® will provide a significant advancement in the treatment of breakthrough cancer pain, addressing the need for more effective and rapid pain relief solutions. For more information about Akela Pharma Inc. and its therapeutic innovations, please visit their website at akelapharma.com.